DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials

by Morgan C, Jin X, Yu X, De Rosa S, Kublin J, Metch B, Keefer M, NIAID H
Published 2012-09-01

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa

by Roux S, Moodie Z, Metch B, Mlisana K, Nchabeleng M, Bekker L, Churchyard G, Gray G, Allen MA, Mathebula M, Bennie T, Kublin J
Published 2009-10-01

Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906)

by Koblin B, Metch B, Morgan C, Novak R, Swann E, Metzger D, Lucy D, Dunbar D, Graham P, Madenwald T, Escamia G, Frank I
Published 2012-09-01

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?

by Moodie Z, Metch B, Bennie T, Latka M, Mathebula M, Roux S, de Bruyn G, Mlisana K, Nchabeleng M, Churchyard G, Bekker L, Gray GE, Allen M, Eaton N, Kublin J
Published 2009-10-01